Sologub T V, Romantsev M G, Shul'diakov A A, Lin'kova Iu N, Radchenko V G, Kovalenko A L
Ter Arkh. 2010;82(10):78-81.
The results of a study of the efficiency of treatment in patients with chronic hepatitis C conducted in a complex of multicenter clinical trials of the impact of various antiviral therapy regimens including the interferon genesis inductor cycloferon are reviewed. Four hundred and seventy-eight patients with hepatitis C virus infection were followed up. The study has demonstrated that the incorporation of cycloferon into the standard treatment regimen, which is manifested by the effect of drug synergism, by producing antiviral, immunomodulating, and antifibrotic effects, is a promising pharmacotherapy for chronic hepatitis C. This treatment is economically sound, reduces the incidence and degree of adverse reactions and increases the quality of life in the patients.
回顾了一项针对慢性丙型肝炎患者治疗效果的研究结果，该研究在一系列多中心临床试验中开展，涉及包括干扰素生成诱导剂环孢素在内的各种抗病毒治疗方案的影响。对478例丙型肝炎病毒感染患者进行了随访。研究表明，将环孢素纳入标准治疗方案，通过产生抗病毒、免疫调节和抗纤维化作用，表现出药物协同效应，是一种治疗慢性丙型肝炎的有前景的药物疗法。这种治疗在经济上是合理的，可降低不良反应的发生率和程度，并提高患者的生活质量。
